The “Cell Cycle” pathway is also enriched by inhibiting Aurora kinase-B and Aurora kinase-A and downregulating TUBB, TUBB4B, MYC and TUBA1A and upregulating CCND3. Another important enriched pathway is the “Acute myeloid leukaemia” pathway by inhibiting RAF1 and down-regulating MYC. We can hence conclude that genes targeted by fenbendazole according to CMap data has biological relevance to leukaemia according to literature. This evidence concerns the gene AURKA and acute myeloid leukemia.